MentalHealthDaily

Anti-CGRP Monoclonal Antibodies to Prevent Chronic Migraine (2023 Review)

by GLOOM

Migraine, a primary headache disorder, significantly impacts the quality of life of millions worldwide. In recent years, the focus has shifted toward developing targeted therapies, particularly monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP), to prevent chronic migraine attacks. A relatively recent comprehensive network meta-analysis (NMA) evaluated the efficacy and safety of various anti-CGRP mAbs, …

How People Feel About Antipsychotics & Mood Stabilizers: Twitter/X Sentiment Analysis (2024 Study)

by GLOOM

Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such as Schizophrenia and related psychotic disorders (SRD) and Bipolar Disorder (BD). Leveraging advanced artificial intelligence (AI) techniques, a comprehensive analysis of 893,289 tweets between 2008 and 2022 revealed significant …

Cannabis-Related Self-Harm & Emergency Room Visits (2010-2021): Increasing Since Legalization

by GLOOM

The legalization and liberalization of cannabis in Canada have sparked debates and concerns regarding its impact on public health, particularly in the context of self-harm behaviors. A comprehensive study in Ontario, Canada, spanning from 2010 to 2021, has revealed significant findings on the relationship between cannabis use and emergency department (ED) visits for self-harm. Highlights: …

Berberine for Alzheimer’s Disease Treatment: Mechanisms & Efficacy (2023 Review)

by GLOOM

In the quest for more effective treatments for Alzheimer’s Disease (AD), berberine, a bioactive compound derived from traditional Chinese medicine, has emerged as a promising candidate. Recent preclinical studies have showcased its potential to combat the debilitating effects of AD, with evidence pointing towards its ability to improve cognitive functions, reduce hallmark AD pathologies such …

Psychedelics vs. Epilepsy & Seizures: Effective Treatment or Exacerbation? (2023 Review)

by GLOOM

Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …

CNQX as a Potential Drug Addiction Treatment via AMPA & Kainate Receptors (Glutamate) (2023 Study)

by GLOOM

The journey to overcome addiction is fraught with challenges, not least due to the limited options available for pharmacological intervention. In recent research, the focus has shifted toward understanding the role of glutamate, a key neurotransmitter in the brain, in the development and persistence of addictive behaviors. One compound, CNQX, which antagonizes certain glutamate receptors, …

T2943 Treats Depression via Epigenetics: HDAC5 Inibitor in Hippocampus (2024 Study)

by GLOOM

Depression remains one of the most pervasive and challenging mental health conditions, affecting millions worldwide with a significant number not responding to traditional treatments. Emerging research underscores the role of histone modifications in depression, pointing towards epigenetic mechanisms as potential targets for novel antidepressants. Specifically, a compound known as T2943 (a histone deacetylase-5 (HDAC5) inhibitor), …